人乳头瘤病毒16/18型DNA检测与E6/E7信使核糖核酸检测在宫颈活检女性中检测高级别宫颈病变（CIN2+）的比较疗效

Comparative efficacy of HPV 16/18 DNA and E6/E7 mRNA testing in detecting high-grade cervical lesions (CIN2+) in women with cervical biopsies.

作者信息

Benvari Sepideh, Aslanimehr Masoumeh, Samiee-Rad Fatemeh, Naserpour-Farivar Taghi, Sadeghi Hamid

机构信息

Infection and Global Health Research Division, School of Medicine, University of St Andrews.

Medical Microbiology Research Center, Qazvin University of Medical Sciences, Iran.

出版信息

Diagn Microbiol Infect Dis. 2025 Mar;111(3):116668. doi: 10.1016/j.diagmicrobio.2024.116668. Epub 2024 Dec 20.

DOI:10.1016/j.diagmicrobio.2024.116668

PMID:39733635

Abstract

The study evaluated the efficacy of HPV 16/18 E6/E7 mRNA detection in women with abnormal cervical histology. A total of 99 cervical biopsy samples were analyzed, including 49 benign, 16 with cervical intraepithelial neoplasia grade 1 (CIN1), 9 with CIN2/3, and 25 with cervical cancers. Samples were tested for HPV 16/18 using both DNA and mRNA RT-PCR methods. The findings revealed a sensitivity of 85.3 % (29/34) for the HPV DNA test and 76.5 % (26/34) for the mRNA test in detecting CIN2+ lesions. Notably, the E6/E7 mRNA test demonstrated greater specificity for CIN2+ at 75.4 % (49/65), compared to 52.3 % (34/65) for the DNA test. The prevalence of positive results for both tests increased with the severity of squamous cell abnormalities. However, the HPV 16/18 E6/E7 mRNA test provided superior specificity, making it a more effective method for cervical cancer screening in this region, offering more precise results than DNA testing alone.

摘要

该研究评估了HPV 16/18 E6/E7 mRNA检测在宫颈组织学异常女性中的疗效。共分析了99份宫颈活检样本，其中49份为良性，16份为宫颈上皮内瘤变1级（CIN1），9份为CIN2/3，25份为宫颈癌。使用DNA和mRNA逆转录聚合酶链反应（RT-PCR）方法对样本进行HPV 16/18检测。结果显示，HPV DNA检测在检测CIN2+病变时的灵敏度为85.3%（29/34），mRNA检测的灵敏度为76.5%（26/34）。值得注意的是，E6/E7 mRNA检测对CIN2+的特异性更高，为75.4%（49/65），而DNA检测的特异性为52.3%（34/65）。两种检测的阳性结果患病率均随鳞状细胞异常的严重程度增加而升高。然而，HPV 16/18 E6/E7 mRNA检测具有更高的特异性，使其成为该地区宫颈癌筛查的更有效方法，比单独的DNA检测提供更精确的结果。